Published online before print March 25, 2004, doi: 10.1161/01.RES.0000126411.29641.08
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2004 American Heart Association, Inc.
Integrative Physiology |
Cell-Demanded Liberation of VEGF121 From Fibrin Implants Induces Local and Controlled Blood Vessel Growth
From the Institute for Biomedical Engineering (M.E., U.S., J.A.H., A.H.Z.), ETH and University of Zurich, Zurich, Switzerland; the Department of Obstetrics and Gynecology (A.H.Z.), University Hospital Zurich, Zurich, Switzerland; the Institute of Anatomy (V.G.D., S.A.T., P.H.B), University of Berne, Berne, Switzerland; and Novartis Pharma AG (C.S., G.M.-B., J.W.), Basel, Switzerland.
Correspondence to Andreas H. Zisch, Department of Obstetrics and Gynecology, University Hospital Zurich, Frauenklinikstr. 10, 8091 Zurich, Switzerland. E-mail andreas.zisch{at}usz.ch
Although vascular endothelial growth factor (VEGF) has been described as a potent angiogenic stimulus, its application in therapy remains difficult: blood vessels formed by exposure to VEGF tend to be malformed and leaky. In nature, the principal form of VEGF possesses a binding site for ECM components that maintain it in the immobilized state until released by local cellular enzymatic activity. In this study, we present an engineered variant form of VEGF, 
2PI1–8-VEGF121, that mimics this concept of matrix-binding and cell-mediated release by local cell-associated enzymatic activity, working in the surgically-relevant biological matrix fibrin. We show that matrix-conjugated 2PI1–8-VEGF121 is protected from clearance, contrary to native VEGF121 mixed into fibrin, which was completely released as a passive diffusive burst. Grafting studies on the embryonic chicken chorioallantoic membrane (CAM) and in adult mice were performed to assess and compare the quantity and quality of neovasculature induced in response to fibrin implants formulated with matrix-bound 2PI1–8-VEGF121 or native diffusible VEGF121. Our CAM measurements demonstrated that cell-demanded release of 2PI1–8-VEGF121 increases the formation of new arterial and venous branches, whereas exposure to passively released wild-type VEGF121 primarily induced chaotic changes within the capillary plexus. Specifically, our analyses at several levels, from endothelial cell morphology and endothelial interactions with periendothelial cells, to vessel branching and network organization, revealed that 2PI1–8-VEGF121 induces vessel formation more potently than native VEGF121 and that those vessels possess more normal morphologies at the light microscopic and ultrastructural level. Permeability studies in mice validated that vessels induced by 2PI1–8-VEGF121 do not leak. In conclusion, cell-demanded release of engineered VEGF121 from fibrin implants may present a therapeutically safe and practical modality to induce local angiogenesis.
Key Words: therapeutic angiogenesis • vascular endothelial growth factor • fibrin • controlled release
This article has been cited by other articles:
 |
|
 |
|
  S. Winnik, M. Klinkert, H. Kurz, C. Zoeller, J. Heinke, Y. Wu, C. Bode, C. Patterson, and M. Moser HoxB5 induces endothelial sprouting in vitro and modifies intussusceptive angiogenesis in vivo involving angiopoietin-2 Cardiovasc Res, August 1, 2009; 83(3): 558 - 565. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Kloxin, A. M. Kasko, C. N. Salinas, and K. S. Anseth Photodegradable Hydrogels for Dynamic Tuning of Physical and Chemical Properties Science, April 3, 2009; 324(5923): 59 - 63. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Sanada, Y. Taniyama, J. Azuma, K. Iekushi, N. Dosaka, T. Yokoi, N. Koibuchi, H. Kusunoki, Y. Aizawa, and R. Morishita Hepatocyte Growth Factor, but not Vascular Endothelial Growth Factor, Attenuates Angiotensin II-Induced Endothelial Progenitor Cell Senescence Hypertension, January 1, 2009; 53(1): 77 - 82. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. H. Walpoth, P. Zammaretti, M. Cikirikcioglu, E. Khabiri, M. K. Djebaili, J.-C. Pache, J.-C. Tille, Y. Aggoun, D. Morel, A. Kalangos, et al. Enhanced intimal thickening of expanded polytetrafluoroethylene grafts coated with fibrin or fibrin-releasing vascular endothelial growth factor in the pig carotid artery interposition model J. Thorac. Cardiovasc. Surg., May 1, 2007; 133(5): 1163 - 1170. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Trentin, H. Hall, S. Wechsler, and J. A. Hubbell Tissue Engineering Special Feature: Peptide-matrix-mediated gene transfer of an oxygen-insensitive hypoxia-inducible factor-1{alpha} variant for local induction of angiogenesis PNAS, February 21, 2006; 103(8): 2506 - 2511. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-L. E. Helm, M. E. Fleury, A. H. Zisch, F. Boschetti, and M. A. Swartz Synergy between interstitial flow and VEGF directs capillary morphogenesis in vitro through a gradient amplification mechanism PNAS, November 1, 2005; 102(44): 15779 - 15784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. C. Weber, H. Cai, M. Ehrbar, H. Kubota, G. Martiny-Baron, W. Weber, V. Djonov, E. Weber, A. S. Mallik, M. Fussenegger, et al. Effects of Protein and Gene Transfer of the Angiopoietin-1 Fibrinogen-like Receptor-binding Domain on Endothelial and Vessel Organization J. Biol. Chem., June 10, 2005; 280(23): 22445 - 22453. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Cao, A. Hong, H. Schulten, and M. J. Post Update on therapeutic neovascularization Cardiovasc Res, February 15, 2005; 65(3): 639 - 648. [Abstract] [Full Text] [PDF]
|
|